CONTROLLED-RELEASE IMPLANTS OF DISULFIRM METABOLITES

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 16801
Amount: $500,000.00
Phase: Phase II
Program: SBIR
Awards Year: 1993
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
64550 Research Rd, Bend, OR, 97701
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Kelly L. Smith
 (503) 382-4100
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE PRINCIPAL OBJECTIVE OF THIS PROJECT IS TO DETERMINE THE TECHNICAL FEASIBILITY OF DEVELOPING A DRUG-RELEASING IMPLANTFOR TREATMENT OF ALCOHOLISM. SPECIFIC AIMS DURING PHASE I ARE TO DEVELOP PROTOTYPE IMPLANTS THAT RELEASE DISULFIRAM METABOLITES AND TO TEST THE EFFICACY OF THESE IMPLANTS IN RATS. THE PROTOTYPE IMPLANTS WILL BE MADE OF BIOERODIBLE POLYMERS THAT WILL BE DESIGNED TO BIOERODE FOLLOWING COMPLETE DRUG DELIVERY. THE METABOLITES HAVE BEEN DETERMINED TO BE MUCH MORE POTENT THAN DISULFIRAM, WHICH SHOULD ALLOW LOWER RELEASE RATES, SMALLER IMPLANTS, AND LONGER DURATIONS. DRUG RELEASE RATES AND DURATIONS FROM PROTOTYPE IMPLANTS WILL BE DETERMINED BOTH IN VITRO AND IN VIVO, AND ENZYME INHIBITION DUE TO THE IMPLANTS WILL BE DETERMINED IN RATS AS A PRELIMINARY MEASURE OF EFFICACY. IFTHIS APPROACH IS SUCCESSFUL, IT COULD GREATLY INCREASE BOTH EFFICACY AND PATIENT COMPLIANCE IN TREATMENT PROGRAMS FOR ALCOHOLISM. THE PRINCIPAL OBJECTIVE OF THIS PROJECT IS TO DETERMINE THE TECHNICAL FEASIBILITY OF DEVELOPING A DRUG-RELEASING IMPLANTFOR TREATMENT OF ALCOHOLISM. SPECIFIC AIMS DURING PHASE I ARE TO DEVELOP PROTOTYPE IMPLANTS THAT RELEASE DISULFIRAM METABOLITES AND TO TEST THE EFFICACY OF THESE IMPLANTS IN RATS. THE PROTOTYPE IMPLANTS WILL BE MADE OF BIOERODIBLE POLYMERS THAT WILL BE DESIGNED TO BIOERODE FOLLOWING COMPLETE DRUG DELIVERY. THE METABOLITES HAVE BEEN DETERMINED TO BE MUCH MORE POTENT THAN DISULFIRAM, WHICH SHOULD ALLOW LOWER RELEASE RATES, SMALLER IMPLANTS, AND LONGER DURATIONS. DRUG RELEASE RATES AND DURATIONS FROM PROTOTYPE IMPLANTS WILL BE DETERMINED BOTH IN VITRO AND IN VIVO, AND ENZYME INHIBITION DUE TO THE IMPLANTS WILL BE DETERMINED IN RATS AS A PRELIMINARY MEASURE OF EFFICACY. IFTHIS APPROACH IS SUCCESSFUL, IT COULD GREATLY INCREASE BOTH EFFICACY AND PATIENT COMPLIANCE IN TREATMENT PROGRAMS FOR ALCOHOLISM.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government